These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9891492)

  • 1. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
    Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
    Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
    Savas B; Cole SP; Tsuruo T; Pross HF
    J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
    Zheng YJ; Zhang J; Wang SM; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
    Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bi-specific F(ab')2 enhances cytolytic activities of LAK cells against human small cell lung cancer (SCLC)].
    Azuma A; Niitani H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1132-7. PubMed ID: 1661346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The over-expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells.
    Dupuis ML; Ramoni C; Yassen A; Samoggia P; Tombesi M; Caserta M; Cianfriglia M
    J Biol Regul Homeost Agents; 1991; 5(4):137-41. PubMed ID: 1687102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis.
    Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M
    Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma.
    Gautam SC; Chikkala NF; Lewis I; Grabowski DR; Finke JH; Ganapathi R
    Anticancer Res; 1992; 12(3):921-5. PubMed ID: 1622150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.
    Zambello R; Trentin L; Feruglio C; Bulian P; Masciarelli M; Cipriani A; Agostini C; Semenzato G
    Cancer Res; 1990 Mar; 50(6):1768-73. PubMed ID: 2106387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a small cell lung cancer variant resistant to lymphokine-activated killer (LAK) cells: association with resistance to a LAK cell-derived, cytostatic factor.
    Tachibana I; Watanabe M; Tanio Y; Hayashi S; Hosoe S; Saito S; Matsunashi M; Osaki T; Shigedo Y; Masuno T
    Cancer Res; 1992 Jun; 52(12):3310-6. PubMed ID: 1350752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
    Schmidt-Wolf IG; Lefterova P; Johnston V; Scheffold C; Csipai M; Mehta BA; Tsuruo T; Huhn D; Negrin RS
    Cell Immunol; 1996 Apr; 169(1):85-90. PubMed ID: 8612299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.
    Kimmig A; Gekeler V; Neumann M; Frese G; Handgretinger R; Kardos G; Diddens H; Niethammer D
    Cancer Res; 1990 Nov; 50(21):6793-9. PubMed ID: 1698543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.
    Treichel RS; Bunuan M; Hahn N; Wee K
    Int J Cancer; 2004 Jan; 108(1):78-85. PubMed ID: 14618619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
    Savas B; Cole SP; Akoglu TF; Pross HF
    Nat Immun; 1992; 11(4):177-92. PubMed ID: 1358293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells.
    Midis GP; Gupta VK; Fabian DF; Lefor AT
    J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
    Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubenimex treatment enhances the susceptibility of gastric cancer cell lines to lymphokine-activated killer cells.
    Iwahashi M; Tanimura H; Yamaue H; Tani M; Noguchi K; Mizobata S; Tsunoda T; Tamai M; Hotta T; Arii K
    Anticancer Res; 1994; 14(4A):1563-8. PubMed ID: 7979186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.